Security key
71902K105
CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO)
CUSIP: 71902K105
Q2 2024 13F Holders as of 30 Jun 2024
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 1,867,063
- Total 13F value
- $557,115
- Share change
- +351,890
- SEC-reported price per share
- $0.30
- Number of holders
- 14
- Value change
- +$77,506
- Number of buys
- 9
- Number of sells
- 2
- Shares outstanding
- 5,169,697
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
14
Top holders
10
CERO full security history
Ownership snapshot
Full 13F holder table
CERO THERAPEUTICS HOLDINGS, INC. SEC filings
CERO THERAPEUTICS HOLDINGS, INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of CERO - CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PHOENIX BIOTECH SPONSOR, LLC
Disclosed value leader
ARCH Venture Management, LLC
Comparable rows
0/15
Latest evidence
31 Mar 2024
3/4/5
13F
Highest disclosed value: $4,433,989
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
ARCH Venture Management, LLC has the largest disclosed position value at $4.43M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARCH Venture Management, LLC's linked filing trail.
Disclosed position value
Top 5
PHOENIX BIOTECH SPONSOR, LLC
$100K
ARCH Venture Management, LLC
$4.43M
Douglas Carl Fisher
$483K
HSG Holding Ltd
$202.5K
Daniel E. Geffken
$100K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PHOENIX BIOTECH SPONSOR, LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$100,000
1,000,000 shares
|
— | 14 Feb 2024 |
| ARCH Venture Management, LLC |
13F
Company
|
—
denominator unverified
|
$4,433,989
1,444,296 shares
|
— | 31 Mar 2024 |
| Douglas Carl Fisher |
3/4/5
President
|
—
mixed-class rows
|
$483,000
48,350 shares
mixed-class rows
|
— | 14 Feb 2024 |
| HSG Holding Ltd |
13F
Company
|
—
denominator unverified
|
$202,499
149,999 shares
|
— | 31 Mar 2024 |
| Daniel E. Geffken |
3/4/5
Chief Financial Officer
|
—
denominator unverified
|
$100,020
10,002 shares
|
— | 14 Feb 2024 |
| JANE STREET GROUP, LLC |
13F
Company
|
—
denominator unverified
|
$81,401
26,515 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
14
Shares
1,867,063
Rows available
14
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
8
Q2 2024 holders
14
Holder diff
6
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|